Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has issued an announcement.
Pharmaron Beijing Co., Ltd. has established a Nomination Committee to enhance its corporate governance by regulating the appointment of directors and senior management. The committee, composed of five directors with a majority being independent non-executive directors, is tasked with researching selection criteria and advising on candidates, aiming to optimize the board’s composition and improve governance structure.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$28.10 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. operates in the pharmaceutical industry, focusing on providing research and development services. The company is involved in the appointment of directors and senior management, optimizing board composition, and improving corporate governance.
Average Trading Volume: 13,234,723
Technical Sentiment Signal: Buy
Current Market Cap: HK$59.02B
See more insights into 3759 stock on TipRanks’ Stock Analysis page.